There are currently 62 active clinical trials seeking participants for Atopic Dermatitis research studies. The states with the highest number of trials for Autism participants are California, Florida, Texas and Ontario.
A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)
NCT05717920
Recruiting
A Phase 2, multicenter, adaptive 2-part clinical trial designed to evaluate the safety and efficacy of ADX-629 alone and in combination with standard-of-care in adults with atopic dermatitis.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/16/2024
Locations: Bexley Dermatology Research, Bexley, Ohio
Conditions: Atopic Dermatitis
Register for Updates
Study of TDM-180935 in Atopic Dermatitis Patients
NCT06363461
Recruiting
Randomized, Vehicle-controlled, Parallel Group Study of TDM-180935 in Atopic Dermatitis Patients
Gender:
All
Ages:
18 years and above
Trial Updated:
04/26/2024
Locations: Site 5, Rolling Meadows, Illinois +6 locations
Conditions: Atopic Dermatitis
Register for Updates
A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
NCT06238817
Recruiting
This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or are intolerant to, or contraindicated to topical corticosteroid (TCS)s and topical calcineurin inhibitor (TCI)s.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Lynn Institute of the Ozarks, Little Rock, Arkansas +105 locations
Conditions: Atopic Dermatitis
Register for Updates
A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)
NCT05277571
Recruiting
The purpose of the study is to investigate the safety and tolerability of single-ascending doses of UCB1381 (intravenous and subcutaneous) in healthy study participants and after repeat intravenous dosing in study participants with atopic dermatitis. Efficacy will be assessed following repeat intravenous dosing versus placebo in study participants with atopic dermatitis.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/25/2024
Locations: Up0110 117, North Little Rock, Arkansas +23 locations
Conditions: Atopic Dermatitis
Register for Updates
Phase 2 Trial of HY209gel in Atopic Dermatitis Patients
NCT06024499
Recruiting
This is a randomized, double-blind, placebo-controlled, multi-center, phase 2 study in patients with mild to moderate Atopic Dermatitis(AD), which consists of 2 parts.
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
04/24/2024
Locations: Cahaba Dermatology Skin Health Center, Birmingham, Alabama +3 locations
Conditions: Atopic Dermatitis, Atopic Dermatitis Eczema, Atopic Dermatitis of Scalp
Register for Updates
A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD)
NCT05704738
Recruiting
The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy and combination therapy treatment in adolescent subjects.
Gender:
All
Ages:
Between 12 years and 17 years
Trial Updated:
04/24/2024
Locations: Cahaba Dermatology and Skin Health Center, Birmingham, Alabama +220 locations
Conditions: Atopic Dermatitis
Register for Updates
A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
NCT05633355
Recruiting
The primary objective of this study is to describe the safety and tolerability of rocatinlimab in adolescents with moderate-to-severe AD.
Gender:
All
Ages:
Between 12 years and 17 years
Trial Updated:
04/24/2024
Locations: Phoenix Childrens Hosptial, Phoenix, Arizona +76 locations
Conditions: Atopic Dermatitis
Register for Updates
Systems Biology of Early Atopy
NCT04798079
Recruiting
The goal of this study is to establish a birth cohort that collects prenatal and early life biosamples and environmental samples and rigorously phenotypes young children for food allergy and Atopic Dermatitis (AD) to identify prenatal and early life markers of high risk for food allergy and AD, as well as biological pathways (endotypes) that result in these conditions. Primary Objectives: To study the role and interrelationships of established and novel clinical, environmental, biological, and... Read More
Gender:
All
Ages:
0 years and above
Trial Updated:
04/23/2024
Locations: Arkansas Children's Hospital, Little Rock, Arkansas +11 locations
Conditions: Allergic Diseases, Food Allergy, Atopic Dermatitis
Register for Updates
Natural History and Genetics of Food Allergy and Related Conditions
NCT02504853
Recruiting
Background: - About 15 million Americans have a food allergy. Because there are no cures or effective prevention or treatment for food allergies, researchers want to learn more about them. Objective: - To learn more about the causes and effects of food allergy and related conditions. Eligibility: People ages 2 99 who have food allergy and/or a related genetic or other condition Their relatives Healthy relatives and volunteers Design: Participants will have at least 3 visits over 1 2 years... Read More
Gender:
All
Ages:
Between 1 day and 99 years
Trial Updated:
04/18/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Food Allergy, Loeys-Dietz Syndrome, Atopic Dermatitis, Eosinophilic Esophagitis
Register for Updates
A Study of LY3872386 in Healthy Participants and Participants With Atopic Dermatitis
NCT06119529
Recruiting
The main purpose of this study is to evaluate the safety and tolerability of LY3872386 in healthy participants and participants with atopic dermatitis. The safety of prednisone is also evaluated in healthy participants. Blood tests will be performed to investigate how the body processes the LY3872386 following single and multiple dosing in healthy participants and participants with atopic dermatitis. Blood tests will also be performed to investigate how the body processes the prednisone in healt... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/18/2024
Locations: CenExel ACT, Anaheim, California +3 locations
Conditions: Healthy, Atopic Dermatitis
Register for Updates
A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE)
NCT05398445
Recruiting
The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy treatment.
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
04/17/2024
Locations: Cahaba Dermatology and Skin Health Center, Birmingham, Alabama +201 locations
Conditions: Atopic Dermatitis
Register for Updates
A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe AD
NCT06224192
Recruiting
The primary objective of this study is to assess successful self-administration of rocatinlimab subcutaneous using devices for injection at home.
Gender:
All
Ages:
Between 12 years and 100 years
Trial Updated:
04/17/2024
Locations: Long Beach Research Institute, Long Beach, California +13 locations
Conditions: Atopic Dermatitis
Register for Updates